Risk factors for melanoma skin cancer

A risk factor is something that increases the risk of developing cancer. It could be a behaviour, substance or condition. Most cancers are the result of many risk factors. The most important risk factor for melanoma skin cancer is ultraviolet radiation (UVR) from the sun and indoor tanning.

The number of new cases of melanoma skin cancer has increased in both men and women over the past 30 years. More men than women develop it. The chance of developing melanoma skin cancer increases with age, but it is also found in adolescents and young adults (15 to 29 years of age).

Lentigo maligna is a very early form of skin cancer (called melanoma in situ). It is sometimes described as a precancerous condition of the skin. If lentigo maligna isn’t treated, it may become melanoma skin cancer that can grow into deeper layers of skin or surrounding tissue. Some of the risk factors for melanoma skin cancer may also cause lentigo maligna. Find out more about lentigo maligna.

Risk factors are generally listed in order from most to least important. But in most cases, it is impossible to rank them with absolute certainty.

Ultraviolet radiation (UVR)

Being in contact with ultraviolet radiation (UVR) is the most important risk factor for developing skin cancer. The sun is the main source of UVR. Indoor tanning equipment, such as tanning beds and sun lamps, is also a source of UVR.

Having a tan means that your skin has been damaged by contact with UVR. UVR can cause sunburns, premature aging, cataracts and skin cancers.

Most cases of melanoma skin cancer are caused by contact with UVR from the sun. It could be from being in the sun on and off during your lifetime or being in the sun early in your life. People who have had at least one blistering sunburn as a child or teenager have a higher risk of developing melanoma later in life. The more sunburns you have had, the greater the risk of melanoma.

Many moles

A mole (melanocytic nevus) is a bump or spot on the skin that is usually brown or pink and has a smooth and regular border. Moles are made up of a group of melanocytes (cells that give skin, hair and eyes their colour). Most people have a few moles.

Most moles are harmless. But you have a higher risk of developing melanoma skin cancer if you have many moles.

Atypical moles

Atypical moles (dysplastic nevi) look different from normal moles. They tend to be larger than 6 mm, while normal moles are usually smaller than 6 mm. Atypical moles have an irregular (uneven) shape with undefined borders, but a normal mole is usually round. Atypical moles often have different colours in them, which can range from pink to dark brown. They can look like a melanoma skin cancer, but they are not cancerous.

Having atypical moles increases your risk of developing melanoma skin cancer. This risk increases with the more atypical moles you have.

Congenital melanocytic nevi

Congenital melanocytic nevi are birthmarks or moles that are present at birth or develop shortly after. They may be classified as small (less than 1.5 cm), medium (1.5 to 19.9 cm) or large (covering more than 5% of the body in preteens or greater than 20 cm in teens or adults).

The larger the congenital melanocytic nevus, the greater the risk of developing melanoma skin cancer.

Familial atypical multiple mole melanoma (FAMMM) syndrome

Familial atypical multiple mole melanoma (FAMMM) syndrome is a hereditary condition where a person has many moles (usually more than 50) that often look different from normal moles. A person with FAMMM also has one or more close relatives with melanoma.

People with FAMMM syndrome have a very high risk of developing melanoma skin cancer.

Other hereditary conditions

The following hereditary conditions can also increase the risk of developing melanoma skin cancer.

Xeroderma pigmentosum is a hereditary condition that affects the skin so it can’t repair sun damage. When someone has xeroderma pigmentosum, their skin changes colour and ages prematurely because it is very sensitive to UVR. They alsohave a high risk of developing melanoma and non-melanoma skin cancers.

Werner syndrome is an inherited condition that causes the skin to age prematurely. Werner syndrome is most common in people of Japanese ancestry. People with this condition have a higher risk of developing melanoma skin cancer.

Retinoblastoma is a type of eye cancer in children. Hereditary retinoblastoma is passed on from a parent to a child. It is caused by an inherited RB1 gene mutation. Children with hereditary retinoblastoma have a higher risk for melanoma later in life.

Light-coloured skin, eyes and hair

People with fair or light-coloured skin have a higher risk of developing melanoma skin cancer than people with other skin types. People with blonde or red hair and blue, green or grey eyes also have a higher risk of developing melanoma. Their risk is greater because people with these features have less melanin. Melanin is what gives colour to your skin, hair and eyes. Experts think that it also helps protect the skin from UVR. People with a fair or light-coloured skin who had very bad sunburns at an early age have the highest risk for melanoma skin cancer.

People with dark (brown or black) skin have a lower risk of developing melanoma. People with dark skin may be more likely to develop a rare type of melanoma called acral lentiginous melanoma. This type of melanoma skin cancer occurs on areas not exposed to the sun, such as the soles of the feet or palms of the hands.

Personal history of skin cancer

People who have already had melanoma skin cancer have a higher risk of developing another primary melanoma. Having had basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) is also linked with a higher risk of developing another skin cancer, including melanoma.

Family history of skin cancer

Your risk of developing melanoma increases if one or more of your first-degree relatives has been diagnosed with melanoma. This may be due to family members having similar skin colour and sun exposure habits. It can also be due to similar genetic mutations, although this is rare.

CDKN2A gene mutation

Sometimes genes can change (mutate) so they increase the risk of developing cancer. These mutated genes can be passed down from parents to their children. If several family members have the same type of cancer, or if family members have related types of cancer, they might share an inherited gene mutation.

About 5% to 25% of families with a higher risk for melanoma have an inherited mutation in the CDKN2A gene. This gene is normally a suppressor gene, which means it helps control the growth of cancer cells. When there is a CDKN2A gene mutation, cancer may develop.

Find out more about genes and cancer.

Weakened immune system

People with a weakened immune system have a higher risk of developing melanoma skin cancer. The immune system can be weakened by certain diseases, such as infection with the human immunodeficiency virus (HIV). It can also be weakened by drugs that people need to take to suppress their immune system after an organ transplant.

Possible risk factors

The following factors have been linked with melanoma skin cancer, but there is not enough evidence to show for sure that they are risk factors. More research is needed to clarify the role of these factors for melanoma skin cancer.

  • melanocortin 1 receptor (MC1R) gene mutation
  • ionizing radiation
  • working with products that contain a group of chemicals called polychlorinated biphenyls (PCBs)
  • PUVA therapy
  • tall adult height

Questions to ask your healthcare team

To make the decisions that are right for you, ask your healthcare team questions about risks.

Expert review and references

  • Aaron DM . Moles (melanocytic nevi) . Beers MH, Berkow R (eds.) . Merck Manual Professional Edition . 2013 : https://www.merckmanuals.com/professional.
  • American Society of Clinical Oncology (ASCO). Genetics of Melanoma. 2011.
  • Archier E, Devaux S, Castela E, et al . Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology. 2012.
  • Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2014. Toronto, ON: Canadian Cancer Society; 2014.
  • Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2017. Toronto, ON: Canadian Cancer Society; 2017.
  • Chang YM, Newton-Bishop JA, Bishop DT, et al . A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. International Journal of Cancer. 2009.
  • Colantonio S, Bracken MB, Beecker J . The association of indoor tanning and melanoma in adults: systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2014.
  • Gandini S, Sera F, Cattaruzza MS, et al . Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. European Journal of Cancer. Elsevier; 2005.
  • Gandini S, Sera F, Cattaruzza MS, et al . Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. European Journal of Cancer. 2005: http://www.ejcancer.com/article/S0959-8049(04)00832-9/fulltext.
  • Gruber SB, Armstrong BK . Cutaneous and ocular melanoma. Schottenfeld D, Fraumeni JF Jr (eds.). Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006: 63:1196-1229.
  • Hale EK, Stein J, Ben-Porat L, et al . Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi - results from the NYU-LCMN registry. British Journal of Dermatology. 2005.
  • Hollenbeak, C.S., Todd, M.M., & Billingsley, E.M., et al . Increased incidence of melanoma in renal transplantation recipients. Cancer. Hoboken, NJ: Wiley-Blackwell, Inc; 2005.
  • International Agency for Research on Cancer (IARC). Volume 75: Ionizing Radiation Part 1: X- and Gamma (y)-Radiation, and Neutrons. 2000: http://monographs.iarc.fr/ENG/Monographs/vol75/mono75.pdf.
  • International Agency for Research on Cancer (IARC). Volume 97: 1,3-Butadiene, Ethylene Oxide and Vinyl Halides (Vinyl Fluoride, Vinyl Chloride and Vinyl Bromide). 2008: http://monographs.iarc.fr/ENG/Monographs/vol97/mono97.pdf.
  • International Agency for Research on Cancer (IARC). Volume 55: Solar and Ultraviolet Radiation. 1992: http://monographs.iarc.fr/ENG/Monographs/vol55/mono55.pdf.
  • International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer . The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. International Journal of Cancer. 2007.
  • Kennedy C, Bajdik CD, Willemze R, et al . The influence of painful sunburns and lifetime sun exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi, and skin cancer. Journal of Investigative Dermatology. 2003.
  • Khalesi M, Whiteman DC, Tran B, Kimlin MG, Olsen CM, Neale RE . A meta-analysis of pigmentary characteristics, sun sensitivity, freckling and melanocytic nevi and risk of basal cell carcinoma of the skin. Cancer Epidemiology. 2013.
  • Krengel S, Hauschild A, Schafer T . Melanoma risk in congenital melanocytic naevi: a systematic review. British Journal of Dermatology. 2006.
  • Lindelof B, Sigurgeirsson B, Gabel H, et al . Incidence of skin cancer in 5356 patients following organ transplantation. British Journal of Dermatology. 2000.
  • Loomis D, Browning SR, Schenck AP, et al . Cancer mortality among electric utility workers exposed to polychlorinated biphenyls. Occupational and Environmental Medicine. 1997.
  • Lynch HT, Shaw TG . Familial atypical multiple mole melanoma (FAMMM) syndrome: history, genetics, and heterogeneity. Familial Cancer. 2016.
  • Mahon SM and Yackzan SG . Skin cancer. Yarbro CH, Wujcki D, Holmes Gobel B (eds.). Cancer Nursing: Principles and Practice. 7th ed. Sudbury, MA: Jones and Bartlett; 2011: 66:1650-1682.
  • Marrett LD, Chu MBH, Atkinson J, et al . An update to the recommended core content for sun safety messages for public education in Canada: a consensus report . Canadian Journal of Public Health . 2016 .
  • Naldi L, Altieri A, Imberti GL, et al . Sun exposure, phenotypic characteristics, and cutaneous malignant melanoma: an analysis according to different clinico-pathological variants and anatomic locations (Italy). Cancer Causes & Control. Springer Netherlands; 2005.
  • National Institutes of Health. Genetics Home Reference: CDKN2A. US National Library of Medicine; 2009.
  • National Institutes of Health. Genetics Home Reference: MC1R. US National Library of Medicine; 2007.
  • National Institutes of Health. Genetics Home Reference: Retinoblastoma. Bethesda, MD: US National Library of Medicine; 2016: https://ghr.nlm.nih.gov/condition/retinoblastoma.
  • National Toxicology Program . 14th Report on Carcinogens . Department of Health and Human Services ; 2016 .
  • Pouplard C, Brenaut E, Horreau C, et al . Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. Journal of the European Academy of Dermatology and Venereology. 2013.
  • Raimondi S, Sera F, Gandini S, et al . MC1R variants, melanoma and red hair color phenotype: a meta-analysis. International Journal of Cancer. 2008.
  • Ribas A, Slingluff Cl Jr, Rosenberg SA . Cutaneous melanoma. DeVita VT Jr, Lawrence TS, Rosenberg SA. Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2015: 94:1346-1394.
  • van der Leest RJ, Flohil SC, Arends LR, de Vries E, Nijsten T . Risk of subsequent cutaneous malignancy in patients with prior melanoma: a systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology. 2015.

Reducing your risk for melanoma skin cancer

The best way to reduce your risk of melanoma is to protect yourself from UV rays. Learn how to lower your risk of developing skin cancer.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2024 Canadian Cancer Society